Navepegritide
Source Navepegritide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Navepegritide (brand name YUVIWEL®) is a long‑acting prodrug of C‑type natriuretic peptide (CNP) approved in the United States for increasing linear growth in children aged two years and older with achondroplasia whose growth plates are still open. It is given once weekly by subcutaneous injection and is being studied for related conditions such as hypochondroplasia.
Mechanism of Action
Navepegritide is converted in the body to active CNP, a peptide that binds natriuretic peptide receptors on chondrocytes and reduces signaling through the fibroblast growth factor receptor‑3 (FGFR3)–MAPK pathway. By dampening this over‑active pathway, it restores endochondral ossification, allowing more normal longitudinal bone growth.
What the Research Shows
A pivotal phase‑2b, double‑blind, placebo‑controlled trial (APPROACH) enrolled 84 children (2‑11 y) with achondroplasia and showed a mean increase of 1.49 cm/year in annualized growth velocity after 52 weeks of weekly 100 µg/kg navepegritide versus placebo (P < .001). Secondary outcomes included modest improvements in tibial‑femoral angle, mechanical axis deviation, and child‑reported physical functioning. A 2025 review of trials in children ≥5 y reported a 5.4 cm/year gain from baseline, with injection‑site reactions as the most common adverse event. A 2026 meta‑analysis of CNP analogs, including navepegritide, found a pooled increase of 1.36 cm/year in growth velocity and similar overall adverse‑event rates to placebo, though injection‑site reactions were more frequent. Safety data across studies indicate low rates of serious treatment‑related events.
Reported Benefits
Clinical data demonstrate that navepegritide accelerates linear growth in children with achondroplasia, with reported gains ranging from about 1.5 cm/year in a controlled trial to over 5 cm/year in open‑label extensions and observational reports. In addition to height, trials noted improvements in lower‑limb alignment and physical‑function quality‑of‑life scores, suggesting potential broader musculoskeletal benefits.
Limitations of the Evidence
Evidence is currently limited to phase‑2b trials and early‑phase extensions; long‑term effects on final adult height, spinal stenosis, foramen magnum size, and other complications remain unproven. Direct head‑to‑head comparisons with other agents (e.g., vosoritide, infigratinib) are lacking, and the meta‑analysis pooled heterogeneous studies, limiting precise efficacy estimates for navepegritide alone.
Safety Considerations
Across studies, navepegritide was generally well tolerated. No treatment‑related serious adverse events or deaths were reported in the APPROACH trial. The most common adverse events were mild injection‑site reactions; no symptomatic hypotension, fractures, or significant laboratory abnormalities were observed. Monitoring for local reactions and routine safety labs is advised.
How It Is Administered
Navepegritide is administered as a once‑weekly subcutaneous injection, typically dosed at 100 µg per kilogram of body weight. The formulation is a prodrug designed for sustained release of active CNP, providing continuous exposure between injections.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
No goal associations recorded yet.
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
No regulatory status recorded yet.
Evidence & Sources
- Journal ArticleModerateSavarirayan R, et al.2026-01-01T00:00:00.000000Z
- Journal ArticleModerateZakheim E, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateKang C2026-01-01T00:00:00.000000Z
- Journal ArticleModerateKamrul-Hasan ABM, et al.2026-01-01T00:00:00.000000Z
- Journal ArticleModerateTaylor-Miller T, Savarirayan R2024-01-01T00:00:00.000000Z
Frequently Asked Questions
What condition is navepegritide approved to treat?
In the United States, navepegritide has received accelerated approval for increasing linear growth in pediatric patients aged two years or older with achondroplasia who have open growth plates.
How does navepegritide differ from growth hormone therapy?
Unlike recombinant growth hormone, which works through systemic anabolic effects, navepegritide delivers CNP to specifically inhibit the overactive FGFR3‑MAPK signaling that limits bone growth in achondroplasia, targeting the underlying molecular defect.
What are the common side effects?
The most frequently reported adverse events are mild injection‑site reactions such as redness or swelling. Serious adverse events have not been observed in the published trials, and no systemic hypotension or fractures were reported.
Is there evidence that navepegritide improves outcomes beyond height?
The APPROACH trial reported modest improvements in lower‑limb alignment (e.g., tibial‑femoral angle) and better scores on a child‑reported physical‑function quality‑of‑life measure, suggesting potential benefits beyond linear growth.
What is known about long‑term safety?
Long‑term data are still emerging. Short‑term studies show an acceptable safety profile, but ongoing open‑label extensions and real‑world studies are needed to assess durability of growth gains and effects on complications such as spinal stenosis.